Introduction: The early identification of precursor lesions followed by appropriate treatment prevents development of cervical cancer and its consequences. Objective: The present study evaluated the influence of the COVID-19 pandemic on cervical cancer screening by comparing the quantity of tests to detect cervical cellular changes performed in São Paulo state in 2019, prior to the detection of SARS-CoV-2 in Brazil, to the first (2020) and second (2021) years following its appearance. Materials and Methods: Data from Fundação Oncocentro de São Paulo (FOSP), the agency that analyses approximately 220,000 Papanicolaou (Pap) tests annually, were reviewed. Results: A median of 1,835 Pap tests were performed in 55 municipalities in 2019. This was reduced to 815 tests in 2020, a 56% decrease (p = 0.0026). In 2021, the median number was 1,745, a 53% increase over 2020 levels (p = 0.0233). The 26 municipalities with >1,000 tests in 2020 had a median reduction from 4,433 in 2019 to 2,580 in 2020 (p = 0. 0046). The 29 municipalities with <1,000 tests had a median reduction from 951 in 2019 to 554 in 2020 (p < 0.0001). There was a 44% reduction in the number of follow-up cytological evaluations from 2019 to 2020, followed by a 30% increase in the following year. However, the percentage of women with a normal finding or with any abnormality remained unchanged. The findings from a histological evaluation of women in São Paulo city indicated that the percent of cases positive for CIN-1 (p < 0.0410) and CIN-3 (p < 0.0012) increased in 2020 and 2021 as compared to 2019 levels. Conclusion: A reduction in testing for cervical cancer in the first year of the COVID-19 pandemic, accompanied by an elevated incidence of precancerous lesions in each of the first 2 years following its initiation, may portend a subsequent increased occurrence of cervical cancer in Brazil.

Journal Section:
Gynecologic Cytopathology
Keywords:
COVID-19 pandemic, Cervical cancer screening, Neoplasia, Papanicolaou test
1.
World Health Organization – Cervical Cancer. [cited 2022 Apr 4]. Available from: https://www.who.int/news-room/fact-sheets/detail/cervical-cancer.
2.
Simms KT, Steinberg J, Caruana M, Smith MA, Lew JB, Soerjomataram I, et al. Impact of scaled up human papillomavirus vaccination and cervical screening and the potential for global elimination of cervical cancer in 181 countries, 2020-99: a modelling study. Lancet Oncol. 2019 Mar;20(3):394–407.
3.
Instituto Nacional de Câncer José Alencar Gomes da Silva. Coordenação de Prevenção e Vigilância. Estimativa 2020 Rio de Janeiro. [cited 2022 Apr 4]. Available from: https://www.inca.gov.br/sites/ufu.sti.inca.local/files//media/document//estimativa-2020-incidencia-de-cancer-no-brasil.pdf.
4.
Ginsburg O, Basu P, Kapambwe S, et al. Eliminating cervical cancer in the COVID-19 era. Nat Cancer. 2021;2:133–4.
5.
Costa RF, Longatto-Filho A, Pinheiro C, Zeferino LC, Fregnani JH. Historical analysis of the Brazilian cervical cancer screening program from 2006 to 2013: a time for reflection. PLoS One. 2015 Sep 24;10(9):e0138945.
6.
Hu B, Guo H, Zhou P, et al. Characteristics of SARS-CoV-2 and COVID-19. Nat Rev Microbiol. 2021;19:141–154.
7.
COVID 19 NO BRASIL. [cited 2022 Apr 5]. Available from: https://infoms.saude.gov.br/extensions/covid-19_html/covid-19_html.html.
8.
DIAGNÓSTICO DE CÂNCER E TRATAMENTO DURANTE A PANDEMIA, ALERTA AOS PACIENTES. [cited 2021 Mar 29]. Available from: http://fosp.saude.sp.gov.br/.
9.
Villain P, Carvalho AL, Lucas E, Mosquera I, Zhang L, Muwonge R, et al. Cross-sectional survey of the impact of the COVID-19 pandemic on cancer screening programs in selected low- and middle-income countries: study from the IARC COVID-19 impact study group; 2021. Int J Cancer. 2021 Jul 1;149(1):97–107.
10.
Oncoguia Equipe. Pandemia reduz exames para diagnóstico de câncer. [cited 2021 Mar 29]. Available from: http://www.oncoguia.org.br/conteudo/pandemia-reduz-exames-para-diagnostico-de-cancer/13756/7/.
11.
Fundação Oncocentro de São Paulo. Diretoria adjunta de Laboratório. [cited 2022 Jan 20]. Available from: http://www.fosp.saude.sp.gov.br/fosp/diretoria-adjunta-de-laboratorio/.
12.
Impacto da COVID no tratamento oncológico. Radar do Câncer. [cited 2021 Sep 15]. Available from: http://radardocancer.org.br/painel/covid/.
13.
Pandemia derruba quase 30 milhões de procedimentos médicos em ambulatórios do SUS. Conselho Federal de Medicina. [cited 2021 Sep 15]. Available from: https://portal.cfm.org.br/noticias/pandemia-derruba-quase-30-milhoes-de-procedimentos-medicos-em-ambulatorios-do-sus/.
14.
Bakouny Z, Paciotti M, Schmidt AL, Lipsitz SR, Choueiri TK, Trinh QD. Cancer screening tests and cancer diagnoses during the COVID-19 pandemic. JAMA Oncol. 2021 Mar 1;7(3):458–60.
15.
Enfermagem Oncológica no Enfrentamento da Pandemia de Covid-19 A, de Souza Ramos R. A Enfermagem Oncológica no Enfrentamento da Pandemia de Covid-19: reflexões e Recomendações para a Prática de Cuidado em Oncologia. Rev Bras Cancerol. 2020;66:e–1007.
16.
Ajenifuja KO, Belinson J, Goldstein A, Desai KT, de Sanjose S, Schiffman M. Designing low-cost, accurate cervical screening strategies that take into account COVID-19: a role for self-sampled HPV typing. Infect Agent Cancer. 2020 Oct 14;15:61PMC7556607.
17.
Ribeiro A, Corrêa F, Migowski A, Leal A, Martins S, Raiol T, et al. Rethinking cervical cancer screening in Brazil post COVID-19: a global opportunity to adopt higher impact strategies. Cancer Prev Res. 2021 Oct;14(10):919–26.
18.
Grupo Técnico de Avaliação e Informações de Saúde (Gais). Coordenadoria de Planejamento de Saúde (CPS), Secretaria de Estado da Saúde. Janeiro 2021, ano 13, número 103. [cited 2023 Jan 9]. Available from: https://portal.saude.sp.gov.br/resources/ses/perfil/profissional-da-saude/destaques//gais_103_vf.pdf.
19.
Mayo M, Potugari B, Bzeih R, Scheidel C, Carrera C, Shellenberger RA. Cancer screening during the COVID-19 pandemic: a systematic review and meta-analysis. Mayo Clin Proc Innov Qual Outcomes. 2021 Dec;5(6): 1109–17.
© 2023 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2023
You do not currently have access to this content.